Tharimmune, Inc., a biotechnology company incorporated in Delaware and listed on The Nasdaq Stock Market under the trading symbol THAR, has announced on June 11, 2024, that it has regained compliance with Nasdaq's minimum bid price requirement. This development follows a previous notification received by the company on June 12, 2023, from Nasdaq indicating that Tharimmune was not meeting the minimum bid price rule necessary for continued listing on The Nasdaq Capital Market. The company's compliance reinstatement ensures its continued listing and trading on the market.

Tharimmune, Inc., a biotechnology company incorporated in Delaware and listed on The Nasdaq Stock Market under the trading symbol THAR, has announced on June 11, 2024, that it has regained compliance with Nasdaq's minimum bid price requirement. This development follows a previous notification received by the company on June 12, 2023, from Nasdaq indicating that Tharimmune was not meeting the minimum bid price rule necessary for continued listing on The Nasdaq Capital Market. The company's compliance reinstatement ensures its continued listing and trading on the market.